Company Analysis Laboratorios Farmaceuticos Rovi, S.A.
1. Summary
Advantages
- Dividends (3.96%) are higher than the sector average (1.76%).
- The stock's return over the last year (74.25%) is higher than the sector average (-34.76%).
- Current debt level 6.47% is below 100% and has decreased over 5 years from 16.57%.
- The company's current efficiency (ROE=34.92%) is higher than the sector average (ROE=13.11%)
Disadvantages
- Price (86.05 $) is higher than fair price (56.77 $)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Laboratorios Farmaceuticos Rovi, S.A. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -0.2% | 0.5% |
| 90 days | 0% | -35.4% | 3.8% |
| 1 year | 74.3% | -34.8% | 23.4% |
LABFF vs Sector: Laboratorios Farmaceuticos Rovi, S.A. has outperformed the "Healthcare" sector by 109.01% over the past year.
LABFF vs Market: Laboratorios Farmaceuticos Rovi, S.A. has outperformed the market by 50.86% over the past year.
Stable price: LABFF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: LABFF with weekly volatility of 1.43% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (86.05 $) is higher than the fair price (56.77 $).
Price is higher than fair: The current price (86.05 $) is 34% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (14.7) is lower than that of the sector as a whole (31.52).
P/E vs Market: The company's P/E (14.7) is lower than that of the market as a whole (46.91).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (5.09) is higher than that of the sector as a whole (3.36).
P/BV vs Market: The company's P/BV (5.09) is higher than that of the market as a whole (-8.98).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.02) is lower than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (3.02) is lower than that of the market as a whole (4.88).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (10.35) is higher than that of the sector as a whole (9.95).
EV/Ebitda vs Market: The company's EV/Ebitda (10.35) is lower than that of the market as a whole (25.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 50.26% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (50.26%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-52.93%).
5.4. ROE
ROE vs Sector: The company's ROE (34.92%) is higher than that of the sector as a whole (13.11%).
ROE vs Market: The company's ROE (34.92%) is higher than that of the market as a whole (-8.23%).
5.5. ROA
ROA vs Sector: The company's ROA (23.55%) is higher than that of the sector as a whole (6.14%).
ROA vs Market: The company's ROA (23.55%) is higher than that of the market as a whole (4.85%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.96% is higher than the average for the sector '1.76%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.96% has been steadily paid over the past 7 years, DSI=0.9.
Weak dividend growth: The company's dividend yield 3.96% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (40.54%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
